The Geography of the GLP-1 Divide The states bearing the nation's heaviest burden of obesity are also the ones where GLP medications consume the largest share of income
Researchers are exploring nanoparticle carriers, enzyme inhibitors, and absorption enhancers to make daily oral GLP-1s easier to take and potentially more effective
Strong investments from pharmaceutical companies are driving innovations and global availability
Newer dual agonists, such as tirzepatide (which targets both GLP-1 and GIP receptors), may have different tolerability profiles, though they can also cause similar gastrointestinal effects
In addition, attention should also be paid to the effect of GLP-1 at different sites of administration and blood concentrations
The glucose-dependent effects theory highlights that both hormones work in glucose-dependent ways but with different patterns